What the research found
This is a market investigation rather than a scientific study. The author tracked expansion of the grey-market peptide supply ecosystem from approximately 25 UK vendors to around 75 within three months, with particular attention to Chinese marketplace listings selling lyophilised vials under unfamiliar names and cosmetic product descriptions. The investigation found that products bearing names of proprietary molecules (notably Retatrutide and Tirzepatide) are being distributed through channels before pharmaceutical approval, often with limited marketplace transparency about identity, source or manufacturing standards.
The author notes a key distinction in the fragmented peptide market: licensed pharmaceuticals occupy one tier; clinics a second; and a much larger grey market comprises local resellers, international suppliers, and direct manufacturer relationships. Supply chains, legal frameworks and quality controls vary substantially across these tiers. The investigation examines whether attractive pricing on Chinese marketplaces represents genuine value or obscures unknown product composition and quality.
Why it matters for you
If you're sourcing peptides outside regulated pharmaceutical channels, this framing is worth internalizing: price alone tells you almost nothing. The author spent approximately $360 per product on independent laboratory testing to verify identity and purity—a cost that dramatically changes the actual price of any "cheap" vial. Without that testing, you have no reliable way to confirm what you're actually injecting: the stated peptide might be absent, impure, contaminated, or non-sterile.
This is directly relevant if you track biomarkers and protocols. Injecting an unverified product means your blood work becomes harder to interpret. Changes in glucose, lipids, or IGF-1 could reflect the intended peptide's effect, batch variation, contamination, or something else entirely. Your training and recovery logs become anecdotal rather than data you can act on. The convenience of price savings evaporates if identity and quality remain unknown.
Caveats
- This is market documentation and journalism, not experimental research—no controlled comparisons or effect measurements
- The author has not yet completed independent testing of ordered samples (Part 2 pending)
- A single identity/purity test per vial does not establish batch consistency, sterility, endotoxin levels or suitability for human injection
- Legal and importation risks vary by jurisdiction and are not addressed here
- No data on prevalence of counterfeiting, contamination or mislabelling in the broader marketplace